20-F/A: Jin Medical International Amends 20-F Filing Due to Internal Control Weakness

Jin Medical International Ltd. amended its annual report on Form 20-F to address a material weakness in internal control over financial reporting and to restate its status as an accelerated filer.

Summary

• Jin Medical International Ltd. filed an amendment to its annual report on Form 20-F for the fiscal year ended September 30, 2024.
• The amendment addresses comments from the SEC regarding Item 15, Controls and Procedures.
• The company restated that it is an accelerated filer for the fiscal year ended September 30, 2024.
• The amendment acknowledges a material weakness in internal control over financial reporting due to a lack of adequately skilled staff with U.S. GAAP knowledge.
• Management concluded that the company's disclosure controls and procedures were not effective as of September 30, 2024.
• The company plans to implement measures to remediate the material weakness, including hiring additional accounting personnel and establishing a financial and system control framework.
• The company is also developing policies and procedures for period-end financial reporting and will initiate U.S. GAAP and SEC financial reporting training programs.
• As an emerging growth company with less than US$1.235 billion in revenue for the fiscal year ended September 30, 2022, the company is exempt from the auditor attestation requirement under Section 404 of the Sarbanes-Oxley Act.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the disclosure of a material weakness in internal control and the conclusion that disclosure controls were ineffective. However, the company is taking steps to address these issues, which provides some mitigation.

Positives

• The company is taking steps to address the identified material weakness in internal control over financial reporting.
• The company plans to hire additional accounting personnel and implement a financial and system control framework.
• The company is developing policies and procedures for period-end financial reporting and will initiate U.S. GAAP and SEC financial reporting training programs.

Negatives

• The company identified a material weakness in its internal control over financial reporting.
• Management concluded that the company's disclosure controls and procedures were not effective as of September 30, 2024.
• The company acknowledges a lack of adequately skilled staff possessing U.S. GAAP knowledge.

Risks

• The company cannot provide assurance that the measures being implemented will be entirely effective in remediating the material weakness in a timely manner or at all.
• Performing a comprehensive assessment of internal control or having an audit of internal control over financial reporting might reveal additional deficiencies.

Future Outlook

The company intends to implement measures to remediate the material weakness in internal control, including hiring additional accounting personnel, establishing a financial and system control framework, developing policies and procedures for period-end financial reporting, and initiating U.S. GAAP and SEC financial reporting training programs.

Management Comments

• Our chief executive officer and chief financial officer concluded that our disclosure controls and procedures as of September 30, 2024, were not effective.
• Our management, including our chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting.

Industry Context

Many companies, especially those recently public or based in China, face challenges in establishing and maintaining robust internal controls that meet U.S. regulatory requirements.

Comparison to Industry Standards

• Companies like Autohome Inc. and 51job, Inc., which are also Chinese companies listed on U.S. exchanges, have faced similar challenges related to internal controls and financial reporting.
• Compared to global benchmarks for internal control effectiveness, such as the COSO framework, the company's identified material weakness indicates a significant deviation from best practices.
• Larger, more established multinational corporations typically have more mature internal control systems and dedicated resources for compliance with U.S. GAAP and SEC regulations.

Stakeholder Impact

• Shareholders may be concerned about the material weakness in internal control and the potential impact on the reliability of financial reporting.
• Employees in the accounting and finance departments may be affected by the planned changes to internal controls and procedures.
• Creditors may assess the company's creditworthiness based on the identified weakness and the steps being taken to address it.

Next Steps

• The company will hire additional accounting personnel.
• The company will establish a financial and system control framework.
• The company will develop policies and procedures for period-end financial reporting.
• The company will initiate U.S. GAAP and SEC financial reporting training programs.

Key Dates

Keywords

internal control, financial reporting, Form 20-F, amendment, U.S. GAAP, SEC, material weakness, disclosure controls, Jin Medical International